Axonyx Announces Acceptance of Four Abstracts Highlighting Phenserine and Posiphen by the 9th International Geneva/Springfield S

Axonyx Inc. (NASDAQ: AXYX) announced today that three
presentations of data on its drug development candidate, Phenserine,
and one presentation of data on its drug development candidate,
Posiphen(TM), will be made at the 9th International Geneva/Springfield
Symposium on Advances in Alzheimer Therapy in Geneva, Switzerland,
being held April 19-22, 2006. Phenserine has been in development by
the Company for the treatment of mild to moderate Alzheimer's disease
(AD) and Posiphen is currently being developed for the treatment of AD
progression.
   The first presentation is entitled "Double Blind
Placebo-Controlled Evaluation Of The Safety and Efficacy of Phenserine
Tartrate for the Treatment of Mild to Moderate Alzheimer's Disease"
and will highlight data from Axonyx's two curtailed Phase III clinical
trials with Phenserine. This will cover a statistically significant
improvement of ADAS-cog score over placebo demonstrated by the 15mg
twice daily group at times following 12 weeks of treatment.
   The second presentation is entitled "Changes of Brain Volumes
during Treatment of Patients with Mild to Moderate Alzheimer's Disease
with Phenserine Tartrate or Placebo." This will report a trend
indicating a preservation of brain volumes for patients on Phenserine
treatment in a small group of 16 AD patients who had brain volumes
assessed before and after 6 months of treatment with Phenserine
tartrate (PT).
   The third presentation is entitled "Effect of Phenserine Treatment
on Brain Amyloid Load and Cerebral Metabolism in Mild Alzheimer
Patients as Studied by PET." This will outline an ongoing clinical
positron emission tomography (PET) study of Phenserine, which was
initiated in November 2004 at the Karolinska Institute, Sweden.
   The fourth presentation is entitled "Brain Beta-Amyloid (1-42) In
Mice Treated Orally with Posiphen Tartrate Is Significantly Lower than
in Vehicle Controls." This will report the reduction of beta-amyloid
(1-42) levels in mouse brain following Posiphen treatment. The
reduction in mice was shown to be associated with blood levels of
Posiphen that were lower than the levels attained in the first phase I
human Posiphen study.
   Axonyx is pleased that the organizers of the Geneva Symposium have
accepted these presentations which will be available to the leading
authorities who attend this important scientific event.

   About Axonyx

   Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in
the acquisition and development of proprietary pharmaceutical
compounds for the treatment of Central Nervous System disorders. The
Company currently has three compounds in development for Alzheimer's
disease, namely Phenserine - a potential symptomatic and disease
progression treatment of mild to moderate Alzheimer's disease (AD),
Posiphen(TM) - a potential disease progression treatment for AD now in
Phase I, and BisNorCymserine (BNC) - a potential symptomatic treatment
of severe AD now in pre-Investigational New Drug (IND) stage. The
Company is looking to identify licensing partners to further the
development of Phenserine.

   This press release may contain forward-looking statements or
predictions. These statements represent our judgment to date, and are
subject to risks and uncertainties that could materially affect the
Company, including those risks and uncertainties described in the
documents Axonyx files from time to time with the SEC, specifically
Axonyx's annual report on Form 10-K. Specifically, with respect to our
drug candidates Phenserine, Posiphen(TM) and BisNorCymserine, Axonyx
cannot assure that: any preclinical studies or clinical trials,
whether ongoing or conducted in the future, will prove successful, and
if successful, that the results can be replicated; safety and efficacy
profiles of any of its drug candidates will be established, or if
established, will remain the same, be better or worse in future
clinical trials, if any; pre-clinical results related to cognition and
the regulation of beta-APP will be substantiated by ongoing or future
clinical trials, if any, or that any of its drug candidates will be
able to improve the signs or symptoms of their respective clinical
indication or slow the progression of Alzheimer's disease; any of its
drug candidates will support an NDA filing, will be approved by the
FDA or its equivalent, or if approved, will prove competitive in the
market; or that Axonyx will have or obtain the necessary financing to
support its drug development programs. Axonyx cannot assure that it
will be successful with regard to identifying (sub-) licensing
partner(s) for any of its compounds, or that any such partner will
successfully develop or commercialize any such compound. Axonyx
undertakes no obligation to publicly release the result of any
revisions to such forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.